{"entity":{"id":"xtop-biotherapeutics","kind":"company","name":"XTOP Biotherapeutics","aka":["XTOP BIOTHERAPEUTICS INC."],"tldr":"XTOP Biotherapeutics is a Worcester, Massachusetts company that designs antibodies binding three targets at once to steer T cells onto cancer cells. Its lead, CB-101, is aimed at colon, pancreatic and lung cancers.","summary":"XTOP Biotherapeutics Inc., of Worcester, Massachusetts, builds multispecific antibodies on its CrossBody platform, which it says lets it tune tumour and T-cell binding to reduce the risk of cytokine release syndrome and conceal tumour-antigen binding to limit toxicity in normal tissue. Its lead, CB-101, is described as a trispecific T-cell engager for colon, pancreatic and lung cancers; the company also announced a research collaboration with Daiichi Sankyo. In fiscal year 2026 the National Cancer Institute funded its SBIR project on CB-101, a trispecific antibody targeting ROR1, EpCAM and CD3 for colorectal cancer and other solid tumours (1R43CA310454-01A1, USD 400,000).","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.xtopbiotherapeutics.com/"},{"label":"Pipeline","url":"https://www.xtopbiotherapeutics.com/pipeline/pipeline"},{"label":"NIH RePORTER: 1R43CA310454-01A1","url":"https://reporter.nih.gov/project-details/11407471"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["immunotherapy"],"technologies":["trispecific-antibodies","t-cell-engager"],"targets":["ror1","epcam","cd3"],"drugs":["cb-101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on xtopbiotherapeutics.com (home and pipeline pages) and the NIH RePORTER record on 4 November 2026. The targets of CB-101 are from the award title; the website does not name them."],"hq":"Worcester, MA","country":"US","companyType":"biotech","website":"https://www.xtopbiotherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":400000,"source":"https://reporter.nih.gov/project-details/11407471","note":"NCI SBIR Phase I (R43) award 1R43CA310454-01A1: Study of CB-101: A Novel First-in-Class Trispecific Antibody Targeting ROR1, EpCAM, and CD3 for the Treatment of Colorectal Cancer and Other Solid Tumors"}]},"route":"/companies/xtop-biotherapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/"}],"drug":[{"id":"cb-101","kind":"drug","name":"CB-101","route":"/drugs/cb-101/"}]}}